| Literature DB >> 33809595 |
Jessica L McCreery1, Kelly A Mackintosh1, Rebekah Mills-Bennett2, Melitta A McNarry1.
Abstract
Bronchiectasis is characterised by airflow obstruction and hyperinflation resulting in respiratory muscle weakness, and decreased exercise capacity. Inspiratory muscle training (IMT) is potentially an alternative treatment strategy to enhance respiratory muscle strength and endurance. Therefore, the aim was to investigate the effects of IMT on those with bronchiectasis. Eighteen participants (10 bronchiectasis) took part in an eight-week, three times a week IMT programme at 80% sustained maximal inspiratory pressure (SMIP). Lung function, respiratory muscle strength and endurance, exercise capacity, physical activity and self-determination theory measures were taken. Participants also took part in a semi-structured interview to assess their perceptions and experience of an IMT intervention. After eight weeks of IMT, bronchiectasis and healthy participants exhibited significant increases in MIP (27% vs. 32%, respectively), SMIP (16% vs. 17%, respectively) and inspiratory duration (36% vs. 30%, respectively). Healthy participants exhibited further improvements in peak expiratory flow and maximal oxygen consumption. Bronchiectasis participants reported high levels of perceived competence and motivation, reporting higher adherence and improved physical ability. Eight weeks of IMT increased inspiratory muscle strength and endurance in those with bronchiectasis. IMT also had a positive effect on perceived competency and autonomy, with bronchiectasis participants reporting improved physical ability and motivation, and high adherence.Entities:
Keywords: bronchiectasis; chronic disease; inspiratory muscle training; mixed methods; quality of life; respiratory
Mesh:
Year: 2021 PMID: 33809595 PMCID: PMC8001489 DOI: 10.3390/ijerph18063051
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Baseline anthropometrics of adults with bronchiectasis and healthy participants.
| Characteristics | Total | Bronchiectasis | Healthy | |
|---|---|---|---|---|
|
| ||||
| Age (years) | 51.9 ± 17.2 | 64.5 ± 10.3 | 36.1 ± 8.5 | <0.05 * |
| Sex (female/male) | (5/13) | (3/7) | (2/6) | 0.886 |
| Height (cm) | 172.6 ± 10.9 | 169.5 ± 11.2 | 176.4 ± 9.7 | 0.183 |
| Weight (kg) | 76.9 ± 16.8 | 81.2 ± 19.7 | 71.5 ± 11.2 | 0.238 |
| BMI (kg·m−2) | 25.8 ± 5.5 | 28.3 ± 6.3 | 22.8 ± 1.8 | 0.024 * |
| WHR (cm) | 1.0 ± 0.1 | 1.0 ± 0.1 | 0.9 ± 0.6 | 0.106 |
BMI, body mass index; WHR, waist-to-hip ratio. * p < 0.05 (significant difference between Bronchiectasis and Healthy groups).
Figure 1Changes in (A) maximal inspiratory pressure (MIP); (B) sustained maximal inspiratory pressure (SMIP); (C) peak expiratory flow (PEF) and (D) inspiratory duration over the eight weeks of an inspiratory muscle training intervention in adults with bronchiectasis and healthy controls. Grey columns represent the mean group response with standard deviation bars. Overlaid lines represent individual responses.
Meaningful clinical difference between baseline, eight weeks and 16 weeks in adults with bronchiectasis.
| Parameters | Mean Difference from Baseline–8 Weeks | % of Participants with Clinically Significant Increase | % of Participants with Clinically Significant Decrease | Effect Size | Mean Difference from 8 Weeks–16 Weeks | % of Participants with Clinically Significant Increase | % of Participants with Clinically Significant Decrease | Effect Size |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| MIP (cmH2O) | 19.6 ± 18.9 * | 40% | 0% | 0.4 | 23.7 ± 27.5 | 0% | 33% | 0.5 |
| MEP (cmH2O) | 3.2 ± 20.3 | 20% | 10% | 0.1 | 4.7 ± 4.1 | 0% | 0% | 0.2 |
| SMIP (PTU) | 66.1 ± 57.8 * | 50% | 0% | 0.7 | 65.8 ± 57.6 | 0% | 0% | 0.2 |
| ID (s) | 3.8 ± 4.0 * | 60% | 0% | 0.2 | 3.4 ± 4.1 | 0% | 0% | 0.1 |
| FEV1 (l) | 0.01 ± 0.2 | 0% | 0% | 0.01 | 0.1 ± 0.1 | 0% | 0% | −0.1 |
| FEV1 %predicted | 0.4 ± 11.7 | 30% | 60% | 0.02 | 7.0 ± 6.7 | 67% | 0% | 0.5 |
| FVC (l) | 0.01 ± 0.2 | 10% | 0% | −0.02 | 0.1 ± 0.1 | 0% | 0% | −0.2 |
| FVC %predicted | −2.0 ± 14.1 | 40% | 40% | −0.2 | 9.0 ± 13.1 | 33% | 0% | 0.9 |
| PEF (L·min−1) | 5.0 ± 49.7 | 20% | 10% | 0.04 | 5.0 ± 9.5 | 0% | 0% | −0.04 |
| FEV1/FVC | 2.1 ± 10.2 | 10% | 0% | 0.1 | 1.3 ± 1.5 | 0% | 0% | 0.1 |
|
| ||||||||
| V | 0.1 ± 1.7 | 10% | 10% | −0.04 | 4.3 ± 5.1 | 0% | 100% | 2.0 |
MIP, maximal inspiratory pressure; MEP, maximal expiratory pressure; SMIP, sustained maximal inspiratory pressure; PTU, pressure time unit; ID, inspiratory duration; s, seconds; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; PEF, peak expiratory flow; Vo2max, maximal oxygen uptake. * p < 0.05.
Self-determination measures after eight weeks of inspiratory muscle training.
| 8 Weeks | 95% Confidence Interval | ||||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| ||
| Treatment Self-Regulation | |||||||
| Autonomous | 4.9 ± 1.4 * | 2.1 ± 0.7 | 2.8 | 0.5 | 1.7 | 4.0 | <0.01 * |
| Controlled | 1.7 ± 0.7 | 1.5 ± 0.3 | 0.2 | 0.3 | −0.4 | 0.8 | 0.411 |
| Amotivation | 1.4 ± 0.6 | 4.3 ± 0.4 * | −2.9 | 0.3 | −3.4 | −2.4 | <0.01 * |
| Perceived Competence | 5.5 ± 1.3 * | 4.6 ± 1.1 | 0.9 | 0.6 | −0.31 | 2.1 | 0.128 |
SEM, standard error of the mean. * p < 0.05 within group differences.